STAT3 and hepatocellular carcinoma: Our data suggest that the drug panobinostat approved by FDA might also prevent liver cancer cells proliferation through HDAC3–STAT3 signaling pathway in HDAC3-overexpressed HCC, while the detail effects and mechanisms of panobinostat for the clinical treatment of HCC remain further studies.